Palantir Technologies (NASDAQ: PLTR) shares fell more than 3% during regular trading on Monday, tracking a broader market weakness. The decline followed cautious remarks last week from Federal Reserve Chair Jerome Powell and President Donald Trump‘s criticism of Powell.
On Wednesday, Powell warned that tariffs could lead to higher inflation and pointed to signs of economic slowdown. His comments unsettled investors and sparked concerns about future federal and commercial spending—key revenue streams for Palantir.
The selloff came despite several notable developments for the company in recent weeks. Palantir was cited in media reports linking it to President Trump’s proposed missile defense system, dubbed the “Golden Dome,” alongside SpaceX and defense firm Anduril. The company also announced a new partnership with AI startup Anthropic to bring its Claude AI model to U.S. government agencies through the Palantir FedStart platform.
In addition, the company secured a fast-tracked deal with NATO for its Maven Smart System NATO (MSS NATO), a military AI platform designed to aid intelligence and battlefield operations. The agreement went from concept to signed contract in just six months, marking a quick turnaround for NATO procurement.
Despite these advancements, Morgan Stanley revised its outlook on the Palantir (NASDAQ: PLTR) stock. The firm lowered its price target from $95 to $90 while maintaining an Equal-Weight rating. While the stock remains up over 300% over the past year, analysts say it is becoming increasingly sensitive to macroeconomic risks rather than company-specific wins.
Salman Akhtar is a finance, stocks, and technology journalist with years of experience across various news organizations. He has contributed his expertise to outlets such as 24NewsHD, TrimFeed, The Voice Pakistan, and TheTechBasic. Salman is passionate about making complex topics accessible to a broad audience. His dedication to delivering accurate and timely information has established him as a trusted voice in the industry. Read Full Bio
